These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 27227699)

  • 1. Defining adherence to prophylaxis in haemophilia.
    Schrijvers LH; Cnossen MH; Beijlevelt-Van der Zande M; Peters M; Schuurmans MJ; Fischer K
    Haemophilia; 2016 Jul; 22(4):e311-4. PubMed ID: 27227699
    [No Abstract]   [Full Text] [Related]  

  • 2. Current prescription of prophylactic factor infusions and perceived adherence for children and adolescents with haemophilia: a survey of haemophilia healthcare professionals in the United States.
    Thornburg CD; Carpenter S; Zappa S; Munn J; Leissinger C
    Haemophilia; 2012 Jul; 18(4):568-74. PubMed ID: 22335526
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term secondary prophylaxis with recombinant activated factor VII (rFVIIa) in haemophilia A with inhibitors: a case report.
    Kubisz P; Plamenová I; Stasko J; Dobrotová M; Hollý P
    Thromb Haemost; 2010 Apr; 103(4):868-70. PubMed ID: 20135075
    [No Abstract]   [Full Text] [Related]  

  • 4. Including the life-time cumulative number of joint bleeds in the definition of primary prophylaxis.
    den Uijl IE; Fischer K
    Thromb Haemost; 2008 May; 99(5):965; author reply 966-8. PubMed ID: 18449430
    [No Abstract]   [Full Text] [Related]  

  • 5. Maintenance of treatment logs by haemophilia patients.
    du Treil S; Rice J; Leissinger CA
    Haemophilia; 2010 May; 16(3):545-7. PubMed ID: 20050930
    [No Abstract]   [Full Text] [Related]  

  • 6. Management of joint bleeding in hemophilia.
    Simpson ML; Valentino LA
    Expert Rev Hematol; 2012 Aug; 5(4):459-68. PubMed ID: 22992238
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Promoting self-management and adherence during prophylaxis: evidence-based recommendations for haemophilia professionals.
    Schrijvers LH; Schuurmans MJ; Fischer K
    Haemophilia; 2016 Jul; 22(4):499-506. PubMed ID: 27075653
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evidence for the benefits of prophylaxis in the management of hemophilia A.
    Hoots WK; Nugent DJ
    Thromb Haemost; 2006 Oct; 96(4):433-40. PubMed ID: 17003919
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prophylaxis in adults with haemophilia.
    Hay CR
    Haemophilia; 2007 Sep; 13 Suppl 2():10-5. PubMed ID: 17685918
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identifying and overcoming barriers to prophylaxis in the management of haemophilia.
    Petrini P
    Haemophilia; 2007 Sep; 13 Suppl 2():16-22. PubMed ID: 17685919
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Joint outcomes in patients with haemophilia: the importance of adherence to preventive regimens.
    Berntorp E
    Haemophilia; 2009 Nov; 15(6):1219-27. PubMed ID: 19659939
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [French guidelines. Long-term prophylaxis for severe haemophilia A and B children to prevent haemophiliac arthropathy].
    Meunier S; Trossaërt M; Berger C; Borel-Derlon A; Dirat G; Donadel-Claeyssens S; Assolant AD; Guérois C; Lutz P; Rafowicz A; Rothschild C; Chambost H;
    Arch Pediatr; 2009 Dec; 16(12):1571-8. PubMed ID: 19960603
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Haemophilia care in children--benefits of early prophylaxis for inhibitor prevention.
    Mancuso ME; Graca L; Auerswald G; Santagostino E
    Haemophilia; 2009 Jan; 15 Suppl 1():8-14. PubMed ID: 19125935
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prophylaxis in patients with haemophilia: introduction.
    Chambost H
    Haemophilia; 2010 Mar; 16 Suppl 2():1-3. PubMed ID: 20132331
    [No Abstract]   [Full Text] [Related]  

  • 15. Effects of primary and secondary prophylaxis on the clinical expression of joint damage in children with severe haemophilia A. Results of a multicenter non-concurrent cohort study.
    Schobess R; Kurnik K; Friedrichs F; Halimeh S; Krümpel A; Bidlingmaier C; Nowak-Göttl U
    Thromb Haemost; 2008 Jan; 99(1):71-6. PubMed ID: 18217137
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Progressing towards optimal management of haemophilia A patients with inhibitors. Foreword.
    Tarantino MD
    Haemophilia; 2013 Jan; 19 Suppl 1():1. PubMed ID: 23278992
    [No Abstract]   [Full Text] [Related]  

  • 17. Difficult clinical challenges in haemophilia: international experiential perspectives.
    Forsyth AL; Giangrande P; Hay CR; Kenet G; Kessler CM; Knöbl PN; Llinás A; Santagostino E; Young G
    Haemophilia; 2012 Jul; 18 Suppl 5():39-45. PubMed ID: 22757683
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-utility analysis of Canadian tailored prophylaxis, primary prophylaxis and on-demand therapy in young children with severe haemophilia A.
    Risebrough N; Oh P; Blanchette V; Curtin J; Hitzler J; Feldman BM
    Haemophilia; 2008 Jul; 14(4):743-52. PubMed ID: 18422610
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Short-term low-dose secondary prophylaxis for severe/moderate haemophilia A children is beneficial to reduce bleed and improve daily activity, but there are obstacle in its execution: a multi-centre pilot study in China.
    Tang L; Wu R; Sun J; Zhang X; Feng X; Zhang X; Luke KH; Poon MC
    Haemophilia; 2013 Jan; 19(1):27-34. PubMed ID: 23231016
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A United Kingdom Haemophilia Centre Doctors' Organization guideline approved by the British Committee for Standards in Haematology: guideline on the use of prophylactic factor VIII concentrate in children and adults with severe haemophilia A.
    Richards M; Williams M; Chalmers E; Liesner R; Collins P; Vidler V; Hanley J;
    Br J Haematol; 2010 May; 149(4):498-507. PubMed ID: 20230411
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.